Similarly, in adults with non-diabetic CKD, SGLT2 inhibitors are recommended for those with an eGFR ≥20 mL/min per 1.73 m2 and UACR >200 mg/g (≥20 mg/mmol) or for those with HF, regardless of albuminuria levels (1A). Here, SLC5A2 is linked to chronic kidney disease.